266 related articles for article (PubMed ID: 30975996)
1. A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers.
Mondal G; Stevers M; Goode B; Ashworth A; Solomon DA
Nat Commun; 2019 Apr; 10(1):1686. PubMed ID: 30975996
[TBL] [Abstract][Full Text] [Related]
2. STAG2 Regulates Homologous Recombination Repair and Sensitivity to ATM Inhibition.
Zhou J; Nie RC; He ZP; Cai XX; Chen JW; Lin WP; Yin YX; Xiang ZC; Zhu TC; Xie JJ; Zhang YC; Wang X; Lin P; Xie D; D'Andrea AD; Cai MY
Adv Sci (Weinh); 2023 Dec; 10(36):e2302494. PubMed ID: 37985839
[TBL] [Abstract][Full Text] [Related]
3. Synthetic lethality of cohesins with PARPs and replication fork mediators.
McLellan JL; O'Neil NJ; Barrett I; Ferree E; van Pel DM; Ushey K; Sipahimalani P; Bryan J; Rose AM; Hieter P
PLoS Genet; 2012; 8(3):e1002574. PubMed ID: 22412391
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.
Bailey ML; O'Neil NJ; van Pel DM; Solomon DA; Waldman T; Hieter P
Mol Cancer Ther; 2014 Mar; 13(3):724-32. PubMed ID: 24356817
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer.
Liu Y; Xu H; Van der Jeught K; Li Y; Liu S; Zhang L; Fang Y; Zhang X; Radovich M; Schneider BP; He X; Huang C; Zhang C; Wan J; Ji G; Lu X
J Clin Invest; 2018 Jul; 128(7):2951-2965. PubMed ID: 29649003
[TBL] [Abstract][Full Text] [Related]
6. Synthetic lethality and cancer: cohesin and PARP at the replication fork.
O'Neil NJ; van Pel DM; Hieter P
Trends Genet; 2013 May; 29(5):290-7. PubMed ID: 23333522
[TBL] [Abstract][Full Text] [Related]
7. Synthetic lethality between the cohesin subunits
van der Lelij P; Lieb S; Jude J; Wutz G; Santos CP; Falkenberg K; Schlattl A; Ban J; Schwentner R; Hoffmann T; Kovar H; Real FX; Waldman T; Pearson MA; Kraut N; Peters JM; Zuber J; Petronczki M
Elife; 2017 Jul; 6():. PubMed ID: 28691904
[TBL] [Abstract][Full Text] [Related]
8. STAG1 vulnerabilities for exploiting cohesin synthetic lethality in STAG2-deficient cancers.
van der Lelij P; Newman JA; Lieb S; Jude J; Katis V; Hoffmann T; Hinterndorfer M; Bader G; Kraut N; Pearson MA; Peters JM; Zuber J; Gileadi O; Petronczki M
Life Sci Alliance; 2020 Jul; 3(7):. PubMed ID: 32467316
[TBL] [Abstract][Full Text] [Related]
9. STAG Mutations in Cancer.
Romero-Pérez L; Surdez D; Brunet E; Delattre O; Grünewald TGP
Trends Cancer; 2019 Aug; 5(8):506-520. PubMed ID: 31421907
[TBL] [Abstract][Full Text] [Related]
10. Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2.
Kim JS; He X; Orr B; Wutz G; Hill V; Peters JM; Compton DA; Waldman T
PLoS Genet; 2016 Feb; 12(2):e1005865. PubMed ID: 26871722
[TBL] [Abstract][Full Text] [Related]
11. Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML.
Tothova Z; Valton AL; Gorelov RA; Vallurupalli M; Krill-Burger JM; Holmes A; Landers CC; Haydu JE; Malolepsza E; Hartigan C; Donahue M; Popova KD; Koochaki S; Venev SV; Rivera J; Chen E; Lage K; Schenone M; D'Andrea AD; Carr SA; Morgan EA; Dekker J; Ebert BL
JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33351783
[TBL] [Abstract][Full Text] [Related]
12. Cohesin mutations in human cancer.
Hill VK; Kim JS; Waldman T
Biochim Biophys Acta; 2016 Aug; 1866(1):1-11. PubMed ID: 27207471
[TBL] [Abstract][Full Text] [Related]
13. Synthetic lethal interaction between the tumour suppressor STAG2 and its paralog STAG1.
Benedetti L; Cereda M; Monteverde L; Desai N; Ciccarelli FD
Oncotarget; 2017 Jun; 8(23):37619-37632. PubMed ID: 28430577
[TBL] [Abstract][Full Text] [Related]
14. Paralogous synthetic lethality underlies genetic dependencies of the cancer-mutated gene
Bailey ML; Tieu D; Habsid A; Tong AHY; Chan K; Moffat J; Hieter P
Life Sci Alliance; 2021 Nov; 4(11):. PubMed ID: 34462321
[No Abstract] [Full Text] [Related]
15. Cohesin mutations are synthetic lethal with stimulation of WNT signaling.
Chin CV; Antony J; Ketharnathan S; Labudina A; Gimenez G; Parsons KM; He J; George AJ; Pallotta MM; Musio A; Braithwaite A; Guilford P; Hannan RD; Horsfield JA
Elife; 2020 Dec; 9():. PubMed ID: 33284104
[TBL] [Abstract][Full Text] [Related]
16. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
17. Repression of Transcription at DNA Breaks Requires Cohesin throughout Interphase and Prevents Genome Instability.
Meisenberg C; Pinder SI; Hopkins SR; Wooller SK; Benstead-Hume G; Pearl FMG; Jeggo PA; Downs JA
Mol Cell; 2019 Jan; 73(2):212-223.e7. PubMed ID: 30554942
[TBL] [Abstract][Full Text] [Related]
18. Cohesin gene mutations in tumorigenesis: from discovery to clinical significance.
Solomon DA; Kim JS; Waldman T
BMB Rep; 2014 Jun; 47(6):299-310. PubMed ID: 24856830
[TBL] [Abstract][Full Text] [Related]
19. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
20. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
